Ming-yuan Chen

This study is for people with advanced nasopharyngeal cancer (a type of nose and throat cancer) that has stopped responding to standard treatments, including PD-1 immunotherapy. Researchers are testing four different drug combinations to see which works best at shrinking tumors. …

This study tests whether adding a targeted drug (MRG003) to precise radiation therapy can help control cancer in people with EGFR-positive tumors that have spread to up to 5 spots. About 200 adults aged 18-75 with controlled primary tumors will receive the combination. The goal i…

This study tests whether a lower dose of radiation, combined with chemotherapy and immunotherapy, works as well as the standard higher dose for people with advanced nasopharyngeal cancer. It includes 456 participants whose tumors shrank or disappeared after initial chemo-immunoth…

This study tests whether adding the drug becotatug vedotin to a standard immunotherapy (PD-1 inhibitor) works better than the immunotherapy alone for people with a certain type of advanced head and neck cancer that can be removed by surgery. About 430 adults with EGFR-positive, C…

This study tests whether using a smaller radiation area (instead of the full standard area) can work just as well for people with advanced nasopharyngeal cancer that has spread. Participants must have already responded to initial chemotherapy and immunotherapy. The goal is to see…